First patient in Skylark Bio’s Phase I/II trial receives SKY-GJB2 gene therapy
The study aims to gather initial study findings by the end of 2026 while further data is expected during 2027.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance